Keytruda Adjuvant Therapy Study Shows Reduced the Risk of Disease Recurrence or Death by More Than 40 Percent Compared to Placebo in Stage III Melanoma

Merck today announced findings from the Phase 3 EORTC1325/KEYNOTE-054 trial investigating Keytruda, Merck’s anti-PD-1 therapy, as adjuvant therapy in resected, high-risk stage III melanoma. Study results showed Keytruda significantly prolonged recurrence-free survival (RFS), reducing the risk of disease recurrence or death by 43 percent compared to placebo in the overall study population.